A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

(2012) Jonathan W. Goldman et al.   CANCER

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

Targeting the HGF/Met signaling pathway in cancer therapy

(2012) Fabiola Cecchi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action

(2011) James Larkin et al.   Expert Review of Anticancer Therapy

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

(2011) A. A. Adjei et al.   ONCOLOGIST

Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy

(2010) Ana Catarina Pinto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

(2008) Zhao-Shi Zeng et al.   CANCER LETTERS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER